Production Commenced — What It Means
Amrutanjan Health Care has operationalized its fifth manufacturing plant, a state-of-the-art facility located approximately 45 km from Hyderabad in the Rangareddy District. The site covers 10 acres and includes a 1.4 lakh square foot built-up area, specifically designed for the production of feminine hygiene products. This facility represents a strategic move to leverage Telangana’s industrial ecosystem and road connectivity to access key markets across India.
By initiating commercial production here, the company significantly scales its manufacturing footprint, moving beyond its traditional pain management roots to aggressively target the high-growth hygiene sector.
Path to This Milestone
This milestone follows a substantial 150 crore investment in greenfield infrastructure. The facility utilizes advanced automation through two high-speed production lines sourced from Japan, which are recognized among the fastest in India’s sanitary napkin industry. Beyond industrial output, the plant integrates sustainable design elements such as rainwater harvesting, an on-site sewage treatment plant, and waste recycling systems.
Future plans include incorporating solar power, aligning with the Make in India initiative and reinforcing the company's commitment to responsible, technology-driven manufacturing processes to meet rising domestic demand for quality hygiene products.
Revenue Impact
With a planned annual capacity of 700 million units, the facility is poised to be a primary driver for the Comfy brand. Amrutanjan has been focused on diversifying its portfolio, and this capacity ramp-up allows for deeper market penetration in the value-driven sanitary napkin segment. Given the company's TTM operating revenue of 502.55 crore, the addition of such large-scale production volume provides a structural pathway for significant topline growth.
The efficient Japanese technology is expected to maintain high precision and quality, supporting operational excellence and potentially improving long-term margins through economies of scale.
Financial Context
Currently, Amrutanjan Health Care maintains a Trendlyne Durability Score of 65, indicating a stable financial health profile. The company reported 10.78 percent annual revenue growth and a 13.93 percent increase in net profit for the previous fiscal year. With a market capitalization of 1496.12 crore and a TTM Price-to-Earnings ratio of 25.83, the stock is trading at a discount to the sector average of 45.05.
This new asset commissioning adds productive capacity to a debt-free framework, strengthening its position within the competitive pharmaceutical and hygiene landscape as it scales its non-balm portfolio.
Sector Tailwinds
The Indian feminine hygiene market is witnessing a shift driven by increasing health awareness and rising disposable incomes in rural and semi-urban areas. Government initiatives and social awareness programs have further accelerated the adoption of branded sanitary products. By establishing a large-scale manufacturing hub in South India, Amrutanjan is well-positioned to capture this growing demand.
The proximity to Hyderabad’s logistical hub reduces supply chain lead times, allowing the company to compete effectively against multinational players while benefiting from the favorable policy environment supporting domestic manufacturing and sustainable industrial practices.
